No trial has tested this combination in people. Each compound below has whatever evidence it has, on its own. Putting two or three of them in one vial does not combine their evidence, and no study has looked at what they do together, in what order, or at what cost. Everything on this page about the pairing is a description of what is claimed for it, not a finding.
What is in it
Not a peptide, and not a failed drug candidate: NAD+ is a coenzyme every living cell makes and remakes for itself, sold in the same catalogues as peptides and marketed as energy, longevity a…
- Evidence
- Limited
- Status
- Not a Peptide
- Documented risks
- 8 · 4 serious
A genuinely interesting discovery — a hormone encoded by the mitochondrial genome rather than the nucleus. The exercise-mimetic and metabolic findings in mice are striking, and after a decad…
- Evidence
- Minimal
- Status
- Research Use Only
- Documented risks
- 7 · 5 serious
An NNMT inhibitor with a real preclinical story and no human one. Every result behind the fat-loss marketing comes from mice given the compound by injection, almost all of it from one labora…
- Evidence
- Minimal
- Status
- Not a Peptide
- Documented risks
- 8 · 4 serious
Why it is sold this way
The stack is sold on a shared story rather than a shared mechanism — all three are associated in the marketing with mitochondrial function, NAD+ availability and metabolic rate. Each is independently popular, and combining them produces a product that can be described using all three sets of claims at once.
What the combination actually has behind it
This is the weakest combination on the page and the one where the components have least in common. Two of the three are not peptides. None of the three has a human trial supporting the marketed use, and the small-molecule component has published mouse pharmacokinetics showing very low oral bioavailability, which is a problem for any oral form. Three sets of preliminary evidence do not add up to one set of good evidence.
| NAD+ (Nicotinamide Adenine Dinucleotide) |
2/5 Limited
Evidence rating 2 out of 5: Limited
Preclinical work plus scattered human reports, uncontrolled use, or negative trials. |
|---|---|
| MOTS-c |
1/5 Minimal
Evidence rating 1 out of 5: Minimal
Animal or laboratory data only. No human efficacy evidence. |
| 5-Amino-1MQ |
1/5 Minimal
Evidence rating 1 out of 5: Minimal
Animal or laboratory data only. No human efficacy evidence. |
| The blend | No human trial of the combination exists. The figure that matters for a mixture is its weakest component, which here is 1 of 5. |
What mixing them makes impossible
With three substances in one vial there is no way to attribute anything to anything. It also multiplies the supply problem: three separately sourced materials, three chances that identity, purity, sterility or endotoxin content is not what the label says, and one product in which any of them could be the cause of a reaction.
Change one thing at a time. This is the most useful rule on the safety page and a fixed mixture breaks it by design. If a blend helps, you cannot say which part helped; if it harms, you cannot say which part harmed, or stop that part alone.
Regulatory status
None of the three is an approved medicine for the marketed use in the United States or the European Union. The regulatory position of each differs and is stated on its own page.
| MOTS-c | Advisory committee recommended Off Category 2 since April 2026 and recommended by the FDA’s advisory committee in July 2026 — but not yet on the 503A bulks list, so not yet lawfully compoundable. |
|---|
The dated record for the compounds this site tracks is on the compounding status page, which is checked against the FDA's own documents rather than against anybody's description of them. A committee recommendation is not FDA action, removal from a list is not permission, and none of it is drug approval.
Related compounds
This page is educational information, not medical advice. It cannot account for your medical history, medications or risk factors. Do not start, stop or change any treatment based on it.